217 related articles for article (PubMed ID: 26995076)
1. [Intravitreal bevacizumab in AMD complicated by submacular hemorrhage].
Bouraoui R; Bouladi M; Kort F; Limaiem R; Mghaieth F; El Matri L
J Fr Ophtalmol; 2016 Mar; 39(3):248-54. PubMed ID: 26995076
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
4. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration.
Kim HS; Cho HJ; Yoo SG; Kim JH; Han JI; Lee TG; Kim JW
Eye (Lond); 2015 Sep; 29(9):1141-51. PubMed ID: 26272443
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
10. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration.
Jain S; Kishore K; Sharma YR
Indian J Ophthalmol; 2013 Sep; 61(9):490-6. PubMed ID: 24104707
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
14. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages.
Rickmann A; Paez LR; Della Volpe Waizel M; Bisorca-Gassendorf L; Schulz A; Vandebroek AC; Szurman P; Januschowski K
PLoS One; 2021; 16(4):e0250587. PubMed ID: 33930041
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
Jonas JB; Tao Y; Schlichtenbrede FC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL
Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
[TBL] [Abstract][Full Text] [Related]
18. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
20. Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
Prieto-Del-Cura M; Villafruela-Güemes I; Recio-Gamo E; Sastre-Ibañez M; Fuentes-Ferrer ME
J Fr Ophtalmol; 2020 Dec; 43(10):989-995. PubMed ID: 33081995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
